Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04959552 · ClinicalTrials.gov registry record

FSL2 Post Approval Study for Pediatric and Young Adults Patients

A clinical trial of Diabete Mellitus, sponsored by Abbott Diabetes Care.

Recruiting
Registry status
550
Enrollment target
3
Study locations

NCT04959552 is a study of Diabete Mellitus that is actively recruiting participants, run by Abbott Diabetes Care. The registered enrollment target is 550 participants, above the 116-participant average among 6 other Diabete Mellitus trials with a reported enrollment target (374% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04959552, a study of Diabete Mellitus, is actively recruiting participants, sponsored by Abbott Diabetes Care.

RECRUITING
Registry status
550 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective, multi-center, non-randomized, single-arm study intended to characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations.

Conditions Studied

Interventions

  • DEVICE FreeStyle Libre 2

Study Locations (3)

Connecticut

  • Yale Pediatric Endocrinology Clinic - New Haven

Missouri

  • The Children's Mercy Hospital - Kansas City

Nevada

  • The DOCS - Las Vegas

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2021-06-01
Est. Completion 2025-12-30

Sponsor

Abbott Diabetes Care

26 total trials

What the Registry Record Tells You About NCT04959552

The ClinicalTrials.gov registry entry for NCT04959552 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 116-participant average among 6 other Diabete Mellitus trials with a reported enrollment target (374% higher). The listed sponsor is Abbott Diabetes Care, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabete Mellitus appearing as the primary indexed condition, and to 1 intervention - of which FreeStyle Libre 2 is the first listed.

NCT04959552 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Missouri, Nevada.

Frequently Asked Questions

What is clinical trial NCT04959552 about?

NCT04959552 is a clinical study titled "FSL2 Post Approval Study for Pediatric and Young Adults Patients". This is a prospective, multi-center, non-randomized, single-arm study intended to characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations.

What is the current status of trial NCT04959552?

This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2021-06-01. Estimated completion is 2025-12-30.

What conditions does trial NCT04959552 study?

This clinical trial studies the following conditions: Diabete Mellitus.

What interventions are being tested in trial NCT04959552?

The interventions under investigation include: FreeStyle Libre 2 (DEVICE).

Who is sponsoring clinical trial NCT04959552?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04959552 being conducted?

This trial has 3 study locations across Connecticut, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabete Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.